<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177123</url>
  </required_header>
  <id_info>
    <org_study_id>INN-007</org_study_id>
    <nct_id>NCT02177123</nct_id>
  </id_info>
  <brief_title>Post Market Study of the InnFocus MicroShunt</brief_title>
  <official_title>Post Market Study to Evaluate Safety and Effectiveness of the InnFocus Microshunt™ (MIDI Arrow) in Patients With Primary Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InnFocus Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InnFocus Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicentric, single arm post market study to gather safety and effectiveness&#xD;
      data on the CE Marked InnFocus MicroShunt (MIDI Arrow) device in primary open angle glaucoma&#xD;
      patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to collect additional safety and effectiveness data on the&#xD;
      InnFocus MicroShunt (MIDI Arrow) in subjects suffering from primary open angle glaucoma who&#xD;
      are inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥&#xD;
      18 mm Hg and ≤ 35 mm Hg and/or where glaucoma progression warrants surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2014</start_date>
  <completion_date type="Actual">November 27, 2017</completion_date>
  <primary_completion_date type="Actual">November 27, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Study Success</measure>
    <time_frame>Month 6, 9, 12, and 24</time_frame>
    <description>Rate of success with respect to IOP at Months 6, 9, 12 and 24 on ITT population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IOP Change</measure>
    <time_frame>Day 1, Day 7, Week 4, Month 3, Month 6, Month 9, Month 12, and Month 24</time_frame>
    <description>IOP relative to the pre-operative value was assessed at each post-operative visit (Day 1, Day 7, Week 4, Month 3, Month 6, Month 9, Month 12, and Month 24).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants Requiring Supplemental Medical Therapy at M12 and M24</measure>
    <time_frame>12 and 24 Months</time_frame>
    <description>Throughout the study, the number of glaucoma supplemental medications (derived as the number of medication classes) required after the IMS procedure.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>InnFocus MicroShunt Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>InnFocus MicroShunt implantation in the anterior chamber of the eye on patients with primary open angle glaucoma after am antiproliferative treatment of mitomycin C (MMC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InnFocus MicroShunt implantation</intervention_name>
    <description>Implantation will include the use of Mitomycin C applied with sponges.</description>
    <arm_group_label>InnFocus MicroShunt Surgery</arm_group_label>
    <other_name>InnFocus MicroShunt</other_name>
    <other_name>MIDI Arrow</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject has mild to moderate primary open glaucoma where the intraocular pressure is&#xD;
             not adequately controlled on maximum tolerated medical therapy and has intraocular&#xD;
             pressure greater than or equal to 18mmHg and less than or equal to 35mmHg while on&#xD;
             glaucoma medications and/or where glaucoma progression warrants surgery.&#xD;
&#xD;
          2. Primary open angle glaucoma diagnosis based on glaucomatous optic nerve damage as&#xD;
             evidenced by any of the following optic disc or retinal nerve fiber layer structural&#xD;
             abnormalities documented on slit lamp stereo biomicroscopy or in stereo disc photos:&#xD;
&#xD;
               1. Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially&#xD;
                  at the inferior or superior poles.&#xD;
&#xD;
               2. Localized abnormalities of the peripapillary retinal nerve fiber layer,&#xD;
                  especially at the inferior or superior poles.&#xD;
&#xD;
               3. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural&#xD;
                  tissue.&#xD;
&#xD;
               4. Disc rim or peripapillary retinal nerve fiber layer hemorrhages.&#xD;
&#xD;
        4) Subject willing to comply with study requirements. 5) Subject who has signed an approved&#xD;
        informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active iris neovascularization, active proliferative retinopathy or other ophthalmic&#xD;
             disease that could confound study results.&#xD;
&#xD;
          2. Iridocorneal endothelial syndrome.&#xD;
&#xD;
          3. Epithelial or fibrous downgrowth.&#xD;
&#xD;
          4. Secondary glaucoma such as post-trauma, pseudo-exfoliative, etc.&#xD;
&#xD;
          5. Chronic ocular inflammatory disease.&#xD;
&#xD;
          6. Prior argon laser, selective laser, or micropulse trabeculoplasty within 90 days of&#xD;
             enrollment.&#xD;
&#xD;
          7. Inability to obtain accurate IOP measurement throughout the study. For example: a&#xD;
             history of corneal surgery, corneal opacities or disease/pathology (Active corneal&#xD;
             infection or Fuchs dystrophy are examples.).&#xD;
&#xD;
          8. Severe anterior or posterior blepharitis.&#xD;
&#xD;
          9. Previous incisional ophthalmic surgery, excluding uncomplicated clear corneal&#xD;
             phacoemulsification (cataract) surgery at least 6 months prior to enrollment.&#xD;
&#xD;
         10. Prior laser peripheral iridotomy.&#xD;
&#xD;
         11. Fellow eye with poorer than 20/200 best-corrected visual acuity (BCVA)&#xD;
&#xD;
         12. Angle closure glaucoma or narrow anatomical chamber angle as identified by gonioscopy&#xD;
             and classified as Shaffer Grade 0 or 1.&#xD;
&#xD;
         13. Previous cyclodestructive procedure.&#xD;
&#xD;
         14. Use of oral hypotensive glaucoma medications for treatment of the fellow eye.&#xD;
&#xD;
         15. Severe anterior or posterior blepharitis.&#xD;
&#xD;
         16. Unwilling to discontinue contact lens use after surgery.&#xD;
&#xD;
         17. Previous incisional ophthalmic surgery, excluding uncomplicated clear corneal&#xD;
             phacoemulsification (cataract) surgery at least 6 months prior to enrollment.&#xD;
&#xD;
         18. Presence of an anterior chamber IOL (AC-IOL).&#xD;
&#xD;
         19. Prior laser peripheral iridotomy.&#xD;
&#xD;
         20. Need for glaucoma surgery combined with other ocular procedures or anticipated need&#xD;
             for additional ocular surgery during the investigational period.&#xD;
&#xD;
         21. Fellow eye with poorer than 20/200 best-corrected visual acuity (BCVA)&#xD;
&#xD;
         22. Known allergy or other contraindication to Mitomycin C (MMC) drug.&#xD;
&#xD;
         23. Angle closure glaucoma or narrow anatomical chamber angle as identified by gonioscopy&#xD;
             and classified as Shaffer Grade 0 or 1.&#xD;
&#xD;
         24. Any condition that prevents the investigational device implantation or trabeculectomy&#xD;
             in the superior region of the study eye (e.g., peripheral anterior synechiae, scleral&#xD;
             staphyloma or conjunctival scarring).&#xD;
&#xD;
         25. Diagnosed degenerative visual disorders not associated with existing glaucoma&#xD;
             condition (e.g., advanced dry or wet macular degeneration or other retinal disorders,&#xD;
             central retinal artery or vein occlusion) or choroidopathy (e.g., choroidal&#xD;
             detachment, effusion, choroiditis, or neovascularization).&#xD;
&#xD;
         26. Central corneal thickness that is less than 450 microns or greater than 620 microns.&#xD;
&#xD;
         27. Previous cyclodestructive procedure.&#xD;
&#xD;
         28. Prior retinal laser procedure conducted for any purpose other than treatment of&#xD;
             retinal tear or hole.&#xD;
&#xD;
         29. Conditions associated with elevated episcleral venous pressure such as active thyroid&#xD;
             orbitopathy, cavernous sinus fistula, Sturge-Weber syndrome, orbital tumors, orbital&#xD;
             congestive disease.&#xD;
&#xD;
         30. Clinically significant sequelae from trauma (e.g., chemical burns, blunt trauma, etc.)&#xD;
&#xD;
         31. Ocular pathology or medical condition for which, in the investigator's judgment, the&#xD;
             following factors would either place the subject at increased risk of complications or&#xD;
             contraindicate device implantation or interfere with compliance to elements of the&#xD;
             study protocol (e.g., ophthalmic examinations, follow-up visits),&#xD;
&#xD;
               1. inability to reliably complete visual field testing over the course of the study,&#xD;
&#xD;
               2. uncontrolled systemic disease (e.g. diabetes, hypertension) that could compromise&#xD;
                  their participation in the study.&#xD;
&#xD;
               3. Disorders that pose a fall risk, as well as compromise ability to take a visual&#xD;
                  field exam and take glaucoma medications (e.g., Parkinson's disease),&#xD;
&#xD;
               4. inability to discontinue use of blood thinners within the surgeon's standard&#xD;
                  preoperative or postoperative instructions.&#xD;
&#xD;
               5. immunodeficiency concerns.&#xD;
&#xD;
               6. known corticosteroid responders whose pressure increases would not allow them to&#xD;
                  withstand the postop corticosteroid regimen.&#xD;
&#xD;
         32. Intraocular silicone oil.&#xD;
&#xD;
         33. Ocular steroid use in the planned study eye or systemic steroid use anytime within&#xD;
             three months of the procedure. (This would not include the use of inhaled or&#xD;
             dermatologic steroids.)&#xD;
&#xD;
         34. Chemotherapy within six months of the screening visit.&#xD;
&#xD;
         35. Use of oral hypotensive glaucoma medications for treatment of the fellow eye.&#xD;
&#xD;
         36. A requirement of general anesthesia for the procedure.&#xD;
&#xD;
         37. Bacterial conjunctivitis&#xD;
&#xD;
         38. Bacterial corneal ulcers&#xD;
&#xD;
         39. Endophthalmitis&#xD;
&#xD;
         40. Orbital cellulitis&#xD;
&#xD;
         41. Bacteremia or septicemia&#xD;
&#xD;
         42. Active scleritis&#xD;
&#xD;
         43. Uveitis&#xD;
&#xD;
         44. Severe dry eye syndrome&#xD;
&#xD;
         45. Severe myopia&#xD;
&#xD;
         46. Pseudo-exfoliative glaucoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Van de Weyer, Optometrist</last_name>
    <role>Study Director</role>
    <affiliation>InnFocus Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Ophtalmologique Universitaire de Grenoble, Hôpital A. Michallon - CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalier Paris Saint-Joseph, Service d'Ophtalmologie</name>
      <address>
        <city>Paris</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pole Ophtalmologique de la Clinique Mutualiste</name>
      <address>
        <city>Pessac</city>
        <zip>33608</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Clinic Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinicovision - Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève, Policlinique d'Ophtalmologie</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 26, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <results_first_submitted>January 26, 2021</results_first_submitted>
  <results_first_submitted_qc>May 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2021</results_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma shunt</keyword>
  <keyword>glaucoma drainage device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 9, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02177123/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02177123/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subjects Suffering From Primary Open Angle Glaucoma</title>
          <description>Subjects suffering from primary open angle glaucoma who are inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥ 18 mm Hg and ≤ 35 mm Hg and/or.where glaucoma progression warrants surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded by Sponsor - other reason</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excluded for medical reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Excl. #31 Ocular pathology or medical condition which would place subject at increased risk</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent-to-Treat (ITT) population included all patients who have signed the informed consent and received the assigned therapy under evaluation (InnFocus MicroShunt).</population>
      <group_list>
        <group group_id="B1">
          <title>Subjects Suffering From Primary Open Angle Glaucoma</title>
          <description>Subjects suffering from primary open angle glaucoma who are inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥ 18 mm Hg and ≤ 35 mm Hg and/or.where glaucoma progression warrants surgery.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Study Success</title>
        <description>Rate of success with respect to IOP at Months 6, 9, 12 and 24 on ITT population</description>
        <time_frame>Month 6, 9, 12, and 24</time_frame>
        <population>The Intent-to-Treat (ITT) population included all patients who have signed the informed consent and received the assigned therapy under evaluation (InnFocus MicroShunt).</population>
        <group_list>
          <group group_id="O1">
            <title>Success With Respect for IOP</title>
            <description>The rates of success reflected sustained control of IOP</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Study Success</title>
          <description>Rate of success with respect to IOP at Months 6, 9, 12 and 24 on ITT population</description>
          <population>The Intent-to-Treat (ITT) population included all patients who have signed the informed consent and received the assigned therapy under evaluation (InnFocus MicroShunt).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IOP Change</title>
        <description>IOP relative to the pre-operative value was assessed at each post-operative visit (Day 1, Day 7, Week 4, Month 3, Month 6, Month 9, Month 12, and Month 24).</description>
        <time_frame>Day 1, Day 7, Week 4, Month 3, Month 6, Month 9, Month 12, and Month 24</time_frame>
        <population>The Intent-to-Treat (ITT) population included all patients who have signed the informed consent and received the assigned therapy under evaluation (InnFocus MicroShunt).&#xD;
IOP data collected after glaucoma re-operation was censored for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>IOP Changes From Baseline</title>
            <description>IOP Changes from Baseline thur all timepoints</description>
          </group>
        </group_list>
        <measure>
          <title>IOP Change</title>
          <description>IOP relative to the pre-operative value was assessed at each post-operative visit (Day 1, Day 7, Week 4, Month 3, Month 6, Month 9, Month 12, and Month 24).</description>
          <population>The Intent-to-Treat (ITT) population included all patients who have signed the informed consent and received the assigned therapy under evaluation (InnFocus MicroShunt).&#xD;
IOP data collected after glaucoma re-operation was censored for this analysis.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Requiring Supplemental Medical Therapy at M12 and M24</title>
        <description>Throughout the study, the number of glaucoma supplemental medications (derived as the number of medication classes) required after the IMS procedure.</description>
        <time_frame>12 and 24 Months</time_frame>
        <population>Patients Taking Glaucoma Supplemental Treatment (Study Eye) ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Need for Glaucoma Supplemental Treatment at M12</title>
            <description>Patients Taking Glaucoma Supplemental Treatment (Study Eye)</description>
          </group>
          <group group_id="O2">
            <title>Need for Glaucoma Supplemental Treatment at M24</title>
            <description>Patients Taking Glaucoma Supplemental Treatment (Study Eye)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Supplemental Medical Therapy at M12 and M24</title>
          <description>Throughout the study, the number of glaucoma supplemental medications (derived as the number of medication classes) required after the IMS procedure.</description>
          <population>Patients Taking Glaucoma Supplemental Treatment (Study Eye) ITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were reported for the duration of the study (approximatively 36 months). This analysis population includes all patients who have signed the informed consent / enrolled in the study.</time_frame>
      <desc>Any untoward medical occurrence, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in subjects, users or other persons whether or not related to the investigational medical device.</desc>
      <group_list>
        <group group_id="E1">
          <title>Subjects Suffering From Primary Open Angle Glaucoma</title>
          <description>Subjects suffering from primary open angle glaucoma who are inadequately controlled on maximum tolerated medical therapy with intraocular pressure ≥ 18 mm Hg and ≤ 35 mm Hg and/or.where glaucoma progression warrants surgery</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Anterior Chamber Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Ulcerative Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Implant Site Dehiscence</sub_title>
                <description>and administration site conditions</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular Pressure Increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Sclerectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Trabeculectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotony Of Eye</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Conjunctival Bleb</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Punctate Keratitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hyphaema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Eyelid Ptosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Flat Anterior Chamber Of Eye</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Ulcerative Keratitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Eye Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Eye Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Allergic Keratitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Anterior Chamber Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Choroidal Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Conjunctival Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Conjunctival Hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Conjunctival Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Corneal Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Iris Adhesions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Posterior Capsule Opacification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Implant Site Dehiscence</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Complication Of Device Insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Encapsulation Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Filtering Bleb Leak</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Anaesthetic Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Suture Related Complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Post Procedural Complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Tenon's Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular Pressure Increased</sub_title>
                <counts group_id="E1" events="35" subjects_affected="26" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Dislocation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Device Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Needle Issue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract Operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Sclerectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Trabeculectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sharon Herbert, Associate Director of Clinical Operations</name_or_title>
      <organization>InnFocus, Inc.</organization>
      <phone>(415) 268-9059</phone>
      <email>sharon.herbert@santen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

